METHOD FOR PREDICTING TYROSINE KINASE INHIBITOR (TKI) RESISTANCE IN PATIENTS SUFFERING FROM CHRONIC MYELOGENOUS LEUKEMIA (CML)
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 22, 2013
app pub date -
Oct 17, 2011
filing date -
Oct 15, 2010
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to a method for determining or predicting the response of a patient diagnosed with chronic myelogenous leukaemia (CML) to treatment with a tyrosine kinase inhibitor. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles and inhibitions thereof thereby diagnosing CML patients resistant to treatment with Imatinib.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully